Nested Therapeutics, a clinical-stage oncology company developing transformative therapies for RAS/MAPK-driven disorders, today reported initial clinical results from its ongoing Phase 1 study ...
Please provide your email address to receive an email when new articles are posted on . Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced ...
“Pharmacological inhibition of p38 MAPK significantly reduced α-SMA and Col3A1 expression in both TGF-β1-stimulated fibroblasts and primary IPF cells” Led by Shan Zhu — with corresponding author Yan Y ...
Dilmapimod, a p38 mitogen-activated protein kinase (MAPK) inhibitor, could be beneficial in neuropathic pain, according to a double-blind, placebo-controlled, two-period crossover trial involving 43 ...
Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model. Background: Chemokine receptors have been shown to regulate the progression ...
Psoriasis is characterized by hyperproliferation of keratinocytes and increased expression of integrins, but the pathological signaling pathway remains unknown. In August 15 Journal of Clinical ...
No potential conflict of interest relevant to this letter was reported. Gaestel M. What goes up must come down: molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results